Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose Computed Tomography Lung Cancer Screening
Integration of immune and molecular markers significantly enhances LDCT screening accuracy. The higher NPV achieved by the combined model allows greater confidence in ruling out malignancy among LDCT-detected nodules, thereby reducing unnecessary follow-up examinations and invasive procedures.
Authors
- Paola Suatoni (ORCID: https://orcid.org/0000-0001-5513-5381)
- Miriam Segale (ORCID: https://orcid.org/0000-0001-9845-1616)
- Roberta Eufrasia Ledda (ORCID: https://orcid.org/0000-0003-3184-2676)
- Mattia Boeri (ORCID: https://orcid.org/0000-0001-7106-3138)
- Federica Sabia (ORCID: https://orcid.org/0000-0001-7334-8962)
- Orazio Fortunato (ORCID: https://orcid.org/0000-0001-9874-7273)
- Alfonso Marchianò (ORCID: https://orcid.org/0000-0003-1379-878X)
- Anna Zanghì (ORCID: https://orcid.org/0009-0000-7147-8480)
- Ugo Pastorino
- Luigi Rolli
- Massimo Moro
- Gabriella Sozzi
Institutions
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jtho.2026.103614
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00